Five Factors That Decide U.S. Market Fit for Health Tech Startups

Entering the U.S. market for health tech startups is primarily a strategy question, not a technology one. Investors and partners prioritize a coherent go-to-market plan, including regulatory pathway, reimbursement rationale, and channel strategy, over the underlying product.

Sofia Rodriguez

October 14, 2026 · 5 min read

For an early-stage digital health, MedTech, or biotech startup, entering the U.S. market is less a technology question than a strategy question. The evidence from consultants who work with ex-U.S. companies entering the American system points to one consistent conclusion: investors and partners respond to a coherent go-to-market plan — regulatory pathway, reimbursement rationale, and channel strategy — far more than to the underlying product. This guide lays out five interconnected factors that determine whether your U.S. entry is credible, and closes with a decision framework you can apply to your own plan.

Navigating the U.S. Health Tech Market: A Strategic Framework

The first factor is recognizing what kind of market you are entering. Blue Matter Consulting, a firm that builds U.S. go-to-market strategies for ex-US digital health companies, describes the American healthcare system as "fragmented (and highly complicated)," and reports rising demand from startups seeking help understanding its drivers and barriers. That fragmentation is not a footnote — it shapes every downstream decision about who buys, who reimburses, and who partners.

The backdrop is favorable but does not substitute for planning. An opinion article published through the U.S. National Library of Medicine notes that health technology startups have become a critical driver of innovation in healthcare delivery, with the COVID-19 pandemic accelerating the trend, and that understanding the sector's market size and growth informs investors, policymakers, and providers about opportunities and challenges. In other words, market growth attracts attention — but attention is not adoption, and adoption is what investors ultimately price.

Regulatory Pathway: Your Foundation for Market Entry

The second factor is a clearly framed regulatory pathway, because it is the foundation on which market access rests. Baker Tilly, a professional services firm whose life sciences specialists include former medical directors, CFOs, health economists, pharmaceutical executives, and epidemiologists, states that achieving market access for an innovative medical device, bio-pharmaceutical agent, or diagnostic test is critical to the sustainability of any life sciences company. Because market access activities touch every part of the product life cycle, the firm advises companies to evaluate their strategies early and identify opportunities to increase their chance of success.

For digital health specifically, Blue Matter's guidance adds a sequencing insight: for prescription digital therapeutics, it recommends gaining real-world experience before seeking FDA clearance, noting that most PDTs aim to be regulated, reimbursed, high-quality clinical interventions, but the U.S. market is still warming up to them. The implication for founders is that regulatory ambition should be calibrated to market readiness — a full-clearance pathway for a product category payers have not yet embraced can burn runway without producing revenue. Note that this is strategic commentary, not legal or regulatory advice; specific pathway decisions require qualified counsel.

Investor Appeal: Beyond Technology, Focus on Go-to-Market

The third factor is how you translate strategy into investor messaging. Blue Matter is direct on this point: navigating reimbursement options and explaining the rationale to investors is a critical first step to gaining confidence in the chosen go-to-market strategy. The firm's framing of its own client work — helping ex-U.S. startups understand the drivers and barriers of the U.S. system — reflects where investor skepticism concentrates: not on whether the technology works, but on whether the founders understand the market they are entering.

This is why go-to-market gaps, rather than technology gaps, tend to sink pitches. An investor evaluating a digital health company is effectively underwriting a commercialization plan: who pays, through what mechanism, and against which competitive alternatives. A startup that can articulate its regulatory posture, its reimbursement rationale, and its channel strategy is de-risking the investment in the terms investors actually use. The National Library of Medicine opinion piece reinforces the demand side — investors look to market size and growth trends to gauge opportunity — but growth alone does not answer the commercialization question. Your go-to-market narrative does.

U.S. Health Tech Market Entry Decision Framework

Use the matrix below to align your decisions across the five factors. The analytical task is to connect your regulatory pathway choice to its downstream consequences for investor messaging, partnership options, and reimbursement viability — so that each strategic area reinforces the others rather than pulling in different directions.

Connecting regulatory pathway choices to investor, partnership, and reimbursement consequences
Strategic Area	Key Consideration	Investor / Partner Impact	Reimbursement Implications
Regulatory pathway	Calibrate clearance ambition to market readiness; for PDTs, Blue Matter recommends real-world experience before seeking FDA clearance	A clear, sequenced pathway de-risks the investment story and demonstrates U.S. market understanding	Regulated, reimbursed positioning is the goal for most PDTs, but the U.S. market is still warming to them
Reimbursement strategy	No standardized pathway exists for most digital health products; CPT, NTAP, and DRG have varying applicability	Per Blue Matter, explaining your reimbursement rationale to investors is a critical first step to GTM confidence	Assess insurance reimbursement potential early and define a plausible pathway to achieve it
Market access planning	Per Baker Tilly, market access affects every part of the product life cycle and is critical to company sustainability	Early, deliberate access planning signals operational maturity to investors and partners	Securing reimbursement for devices and technologies requires structured steps, not reactive fixes
Partnership / channel	Map the competitive landscape for "good enough" incumbents and partnership gaps	Big tech (Amazon), retail pharmacies (CVS), and employers (Costco) are emerging buyers and partners seeking to fill service gaps	Channel choice shapes which reimbursement mechanisms and evidence requirements apply
Investor positioning	Lead with go-to-market knowledge, not technology alone	Investor rejection typically traces to GTM gaps — regulatory, quality, or commercialization planning	A credible reimbursement narrative is the proof point of market knowledge investors look for

Connecting regulatory pathway choices to investor, partnership, and reimbursement consequences

Strategic Area

Key Consideration

Investor / Partner Impact

Reimbursement Implications

Regulatory pathway

Calibrate clearance ambition to market readiness; for PDTs, Blue Matter recommends real-world experience before seeking FDA clearance

A clear, sequenced pathway de-risks the investment story and demonstrates U.S. market understanding

Regulated, reimbursed positioning is the goal for most PDTs, but the U.S. market is still warming to them

Reimbursement strategy

No standardized pathway exists for most digital health products; CPT, NTAP, and DRG have varying applicability

Per Blue Matter, explaining your reimbursement rationale to investors is a critical first step to GTM confidence

Assess insurance reimbursement potential early and define a plausible pathway to achieve it

Market access planning

Per Baker Tilly, market access affects every part of the product life cycle and is critical to company sustainability

Early, deliberate access planning signals operational maturity to investors and partners

Securing reimbursement for devices and technologies requires structured steps, not reactive fixes

Partnership / channel

Map the competitive landscape for "good enough" incumbents and partnership gaps

Big tech (Amazon), retail pharmacies (CVS), and employers (Costco) are emerging buyers and partners seeking to fill service gaps

Channel choice shapes which reimbursement mechanisms and evidence requirements apply

Investor positioning

Lead with go-to-market knowledge, not technology alone

Investor rejection typically traces to GTM gaps — regulatory, quality, or commercialization planning

A credible reimbursement narrative is the proof point of market knowledge investors look for

The reasoning path is straightforward: your regulatory choice sets what you can claim and when; your reimbursement assessment determines whether the claim is commercially meaningful; your channel analysis determines who delivers it; and together they form the investor narrative. A lower-burden entry with early real-world evidence may suit a category the market is still warming to, while a full-clearance, reimbursement-led strategy demands a longer runway and a more developed payer case. Neither is universally right — the trade-off is between speed of entry and depth of defensibility, and your fundraising timeline should match the path you choose.